Literature DB >> 3851691

Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide.

A F Brownbill, D G Braun, P Dukor, G Schumann.   

Abstract

Single intranasal applications of MTP-PE, a lipophilic muramyl peptide, induce tumouricidal and tumouristatic leucocytes in the lungs of rats. In ex vivo assays the tumouristatic activity was detectable for 8 days after drug administration. By separation of the effector cells on Ficoll-Hypaque gradients, it was shown that both neutrophils and macrophages are responsible for this activity. Using the B16/BL6 melanoma system in mice, there was a high survival rate after repeated intranasal applications of MTP-PE.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3851691     DOI: 10.1007/bf00199767

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues.

Authors:  G Lopez-Berestein; K Mehta; R Mehta; R L Juliano; E M Hersh
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

2.  The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process.

Authors:  I J Fidler
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

3.  Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastasis.

Authors:  I J Fidler; G Poste
Journal:  Prog Clin Biol Res       Date:  1981

4.  In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes.

Authors:  S Sone; I J Fidler
Journal:  Cell Immunol       Date:  1981-01-01       Impact factor: 4.868

5.  Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes.

Authors:  K Mehta; G Lopez-Berestein; E M Hersh; R L Juliano
Journal:  J Reticuloendothel Soc       Date:  1982-08

6.  Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells.

Authors:  W C Koff; I J Fidler; S D Showalter; M K Chakrabarty; B Hampar; L M Ceccorulli; E S Kleinerman
Journal:  Science       Date:  1984-06-01       Impact factor: 47.728

7.  Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.

Authors:  I J Fidler; Z Barnes; W E Fogler; R Kirsh; P Bugelski; G Poste
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

8.  Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.

Authors:  S Sone; S Mutsuura; M Ogawara; E Tsubura
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

9.  Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.

Authors:  I J Fidler; A Raz; W E Fogler; R Kirsh; P Bugelski; G Poste
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

10.  Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

Authors:  I J Fidler; S Sone; W E Fogler; Z L Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

View more
  2 in total

Review 1.  Therapy of disseminated melanoma by liposome-activated macrophages.

Authors:  I J Fidler
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 2.  Macrophages and cancer.

Authors:  P W Whitworth; C C Pak; J Esgro; E S Kleinerman; I J Fidler
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.